Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

LON/0A9G stock hub

LON/0A9G has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0A9Gis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

29.2M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0A9G

In the news

Latest news · LON/0A9G

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-82.2

P25 n/aP50 n/aP75 n/a

ROIC-44.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0A9G market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

152

Groups with data

Currency

USD

Showing 152 of 152 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	39
Employees Change	3%
Employees Change Percent	9.09
Enterprise value	$-697,117
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	$29.2M
Price	$0.24
Price currency	USD
Rev Per Employee	9,525.64x
Sic	2836
Symbol	lon/0A9G
Website	https://www.mereobiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-106.42%
EV Earnings	0.02x
EV/FCF	0.03x
FCF yield	-78.76%
P/B ratio	0.96x
P/S ratio	78.7x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	73.4%
Gross Profit	$272,681
Gross Profit Growth3 Y	-31.58%
Net Income	$-31.1M
Pretax Margin	-8,375.6%
Profit Per Employee	$-797,830
ROA	-39.41
Roa5y	-29.09
ROCE	-92.65
ROE	-82.21
Roe5y	-47.28
ROIC	-44.41

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-89.88%
Cagr3y	-42.76%

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$34.1M
Cash	$30.5M
Current Assets	$33M
Current Liabilities	$3.2M
Debt	$150,086
Debt Equity	$0
Debt FCF	$-0.01
Equity	$30.4M
Interest Coverage	-151.2
Liabilities	$3.7M
Long Term Assets	$1.1M
Long Term Liabilities	$560,166
Net Cash	$30.3M
Net Cash By Market Cap	$104
Net Cash Growth	-35.64%
Net Debt Equity	$-1
Tangible Book Value	$30M
Tangible Book Value Per Share	$0.19
WACC	5.78

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.46
Net Working Capital	$-53,496
Quick ratio	9.99
Working Capital	$30.3M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-7.77%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-89.86%
200-day SMA	1.21
3Y total return	-81.25%
50-day SMA	0.33
50-day SMA vs 200-day SMA	50under200
All Time High	5.01
All Time High Change	-95.36%
All Time High Date	2024-08-23
All Time Low	0.22
All Time Low Change	5.73%
All Time Low Date	2026-05-07
ATR	0.03
Beta	0.19
Ch YTD	-35.03
High	0.24
High52	3.03
High52 Date	2025-07-07
High52ch	-92.02%
Low	0.23
Low52	0.22
Low52 Date	2026-05-07
Low52ch	9.77%
Ma50ch	-30.3%
Price vs 200-day SMA	-80.81%
RSI	30.85
RSI Monthly	31.91
RSI Weekly	26.11
Sharpe ratio	-0.61x
Sortino ratio	-0.71
Total Return	-7.77%
Tr YTD	-35.03
Tr1m	-27.56%
Tr1w	-10.54%
Tr3m	-44.17%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-28.6M
Operating margin	-7,711.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	114,465,687%
Shares Qo Q	0.06%
Shares Yo Y	7.77%
Short Ratio	4.63

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-28.7M
Average Volume	61,176.9x
Bv Per Share	0.19
CAPEX	$-14,860
Ch1m	-27.56
Ch1w	-10.54
Ch1y	-89.86
Ch3m	-44.17
Ch3y	-81.26
Ch6m	-87.01
Change	3.83%
Change From Open	4.18
Close	0.23
Days Gap	-0.34
Depreciation Amortization	456,245.7
Dollar Volume	14,843.6
Earnings Date	2026-05-11
EBIT	$-28.6M
EBITDA	$-28.2M
EPS	$-0.2
F Score	2
FCF	$-23M
FCF EV Yield	3,303.08x
Financing CF	242,961
Fiscal Year End	December
Founded	2,015
Investing CF	-14,860
Is Primary Listing	0
Last Earnings Date	2025-11-12
Last Report Date	2025-12-31
Ma150	1.04
Ma150ch	-77.55%
Ma20	0.29
Ma20ch	-20.42%
Net CF	-21,405,830
Next Earnings Date	2026-05-11
Open	0.23
Position In Range	79.51
Ppne	279,468.8
Price Date	2026-05-08
Ptbv Ratio	0.97
Relative Volume	1x
Revenue	371,500x
SBC By Revenue	1,519.6x
Share Based Comp	5,645,314
Tr6m	-87.01%
Volume	61,464
Z Score	25.39

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0A9G pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0A9G stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0A9G?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0A9G momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

30.9

Neutral momentum band

Price vs 200-day MA

-80.8%

50/200-day relationship not available

Beta (5Y)

0.19

Less volatile than the market

Sharpe ratio

-0.61

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0A9G

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0A9G stock rating?

lon/0A9G is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0A9G analysis?

The full report lives at /stocks/lon/0A9G/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0A9G?

The latest report frames lon/0A9G around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0A9G page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.